Infex partners with Alderley Analytical to provide PK and ADA analysis for RESP-X program

The image portrays a team of professionals from Alderley Analytical, engaged in a discussion in a relaxed, informal setting. The group is seated across from each other on comfortable, modern furniture, fostering a sense of open dialogue and collaboration. The presence of a plant hanging overhead and the natural light from the windows contribute to a warm and inviting atmosphere, emphasizing a work environment that values communication and team cohesion. This scene likely represents a moment of strategic planning, idea sharing, or team building, illustrating the company's commitment to fostering a collaborative and supportive workplace culture. The diverse team, shown in professional attire, reflects a range of roles and expertise within Alderley Analytical, highlighting the multidisciplinary approach the company employs to achieve excellence in bioanalytical services. This image effectively conveys the human element of Alderley Analytical, showcasing the professionals behind the science and their collaborative efforts to drive innovation and maintain high standards in their field.
This image features the logo of Infex Therapeutics, a company specializing in developing treatments for infectious diseases. The logo consists of a stylized

New deal

Infex Therapeutics has today announced a deal with Alderley Analytical, to support PK and ADA analysis of Infex’s RESP-X program.

RESP-X is an anti-virulence therapy in-licensed from Japanese pharma company Shionogi. It is designed to help the body tackle Pseudomonas aeruginosa infections, a hard to treat drug-resistant pathogen recognised by the WHO as a critical threat to human health. A novel humanised monoclonal antibody, RESP-X does not kill bacteria directly but deactivates a mechanism that prevents the immune system from acting against the infection.

Dr Peter Jackson, CEO of Infex Therapeutics, said: “I am delighted to see Infex working with Alderley Analytical to support for our RESP-X program. Alderley Analytical are a key part of the Alderley Park scientific community, and collaborations such as this really showcase the North West as a UK centre of excellence in infectious disease research.

“RESP-X is designed as a preventative treatment against non-cystic fibrosis bronchiectasis, a long-term condition where the airways of the lungs become abnormally widened, leading to a build-up of excess mucus that can make the lungs more vulnerable to infection. Patients can become chronically infected with Pseudomonas, significantly reducing their quality of life. There is high, unmet need, with millions of patients worldwide at risk of this condition, and no approved preventative therapy.”

Liz Thomas, CEO for Alderley Analytical, said ‘The team at Alderley Analytical is proud to support Infex for their RESP-X program in this important area where there is such high, unmet, need’.

Contact us now to learn more

Contact Us